+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Biosimilar Monoclonal Antibodies market worth $6.6bn in 2025” says Visiongain Report

28 February 2020
Pharma

Visiongain has published a new report Global Biosimilar Monoclonal Antibodies Forecast 2020-2030: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Biosimilar monoclonal antibodies (mAbs) form an emerging sector in pharmaceuticals. As patents for some of the industry’s top-selling biological drugs (biologics) expire, companies have chosen to invest in the development of biosimilars.

The lead analyst of the report commented "Over the course of the forecast period, this market will expand rapidly following patent expiries of several leading innovator products and the approval of biosimilar monoclonal antibodies on the developed markets. Biosimilar versions of new biologic therapies will drive growth in this market. However, there are several biosimilar products in the development pipeline for each of the compounds discussed in this report; competition between these products will restrict revenue generation and result in a fragmented market."

Leading companies featured in the report include BIOCAD, Biocon, BioXpress, Celltrion, Coherus Biosciences, Gene Techno Science and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever